ELV
Elevance Health, Inc. · Healthcare · Healthcare Plans
Last
$319.99
−$3.07 (−0.95%) 4:00 PM ET
After hours $319.02 −$0.97 (−0.30%) 6:13 PM ET
Prev close $323.05
Open $326.03
Day high $326.03
Day low $311.27
Volume 3,971,646
Avg vol 1,864,807
Mkt cap
$70.63B
P/E ratio
12.70
FY Revenue
$199.13B
EPS
25.19
Gross Margin
25.56%
Sector
Healthcare
AI report sections
ELV
Elevance Health, Inc.
No AI report section text found yet for this symbol.
AI summarized at 6:52 PM ET, 2025-04-04
Volume vs average
Intraday (cumulative)
+290% (Above avg)
Vol/Avg: 3.90×
RSI
38.31 (Weak)
Weak (30–40)
MACD momentum
Intraday
-0.02 (Weak)
MACD: -0.67 Signal: -0.64
Short-Term
-1.00 (Weak)
MACD: -5.53 Signal: -4.53
Long-Term
-1.45 (Weak)
MACD: -4.62 Signal: -3.18
Intraday trend score 47.50

Latest news

ELV 12 articles Positive: 1 Neutral: 7 Negative: 4
Negative Investing.com • Timothy Fries
Humana Stock Down as Medicare Rate Proposal Hits Insurers

Humana shares plummeted 13.49% in premarket trading following the Trump administration's proposal for nearly flat Medicare Advantage payment rates for 2027, with only a 0.09% net average payment increase versus Wall Street expectations of 4-6%. The broader health insurance sector also suffered significant losses, with CVS Health, UnitedHealth Group, and Elevance Health all declining sharply.

HUM CVS UNH ELV Medicare Advantage payment rates health insurance CMS proposal
Sentiment note

Stock dropped 6.90% in after-hours trading as a health insurance provider impacted by the low Medicare Advantage payment rate increase and proposed elimination of certain billing practices.

Negative Benzinga • Vandana Singh
Medicare Shock Sends UnitedHealth, Humana And CVS Tumbling

The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.

UNH HUM CVS ALHC Medicare Advantage CMS payment rates health insurers
Sentiment note

Stock dropped 7.14% due to exposure to Medicare Advantage plans facing reduced payment growth in 2027.

Neutral Benzinga • Vandana Singh
UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates

UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.

UNH CI CVS ELV health insurance ACA rebates Medicare Advantage hospital prices
Sentiment note

Mentioned as appearing before House panels alongside other insurers but no specific company actions or statements reported in the article.

Positive Investing.com • Damian Nowiszewski
3 Beaten-Down Stocks Ready to Kick Off 2026 on the Front Foot

As US stocks start 2026 with positive momentum and the S&P 500 near record highs above 6,900 points, three previously underperforming stocks show signs of recovery. Flowco Holdings is forming a rounding pattern with potential upside to $26, Elevance Health is testing key resistance at $360 with a path to $450, and Matador Resources shows strong fundamentals with a 50% fair value gap and potential recovery above $53.

FLOC ELV MTDR stock recovery beaten-down stocks 2026 outlook S&P 500 technical analysis
Sentiment note

Rebounded from long-term lows and testing key resistance at $360. Potential for further gains toward $450 if resistance breaks, closing 11% of gap to fair value estimate.

Neutral The Motley Fool • Jonathan Ponciano
Why a 63% Vertex Selloff Didn’t Scare Off a New $13 Million Investor

Hyperion Capital Advisors acquired 540,000 shares of Vertex (VERX) worth $13.39 million in Q3, making it the fund's third-largest holding. Despite a 63% stock decline over the past year, the investment signals confidence in Vertex's underlying business fundamentals, including 12.7% revenue growth, 30% cloud revenue growth, and strong cash generation with a $150 million share buyback authorization.

VERX GOOG GOOGL ELV institutional investment tax technology software stocks value investing
Sentiment note

Listed as second-largest holding in Hyperion's portfolio (8.9% of AUM). Mentioned as part of fund's preference for durable cash-generating businesses, but no specific analysis provided.

Neutral Benzinga • Vandana Singh
White House Set To Unveil Framework To Extend Obamacare Subsidies

The White House is preparing to introduce a healthcare framework to extend Affordable Care Act subsidies, proposing a two-year extension with updated eligibility limits and measures to control premium increases affecting approximately 22 million Americans.

OSCR CI CNC ELV Obamacare healthcare subsidies insurance costs ACA
Sentiment note

Proposed subsidy extensions might influence healthcare insurance landscape

Neutral Investing.com • Dan Schmidt
Getting Defensive: 3 Dividend Payers Reporting Strong Q3 Earnings

With market volatility increasing, the article highlights three dividend-paying stocks that reported strong Q3 earnings: Travelers Companies, Elevance Health, and Church & Dwight. These stocks offer potential stability and consistent income amid uncertain market conditions.

TRV ELV CHD dividend stocks market volatility Q3 earnings defensive investing
Sentiment note

Beat earnings estimates with 12% YOY operating revenue growth, but facing margin pressures and uncertain stock direction

Neutral Benzinga • Vandana Singh
Centene And Oscar Health Stocks Sink After Molina Warning

Molina Healthcare reported disappointing annual guidance, causing stocks of healthcare insurance providers Centene and Oscar Health to decline. The company expects higher medical cost trends across segments, particularly in the Marketplace, impacting investor confidence.

MOH CNC OSCR ELV healthcare insurance medical costs earnings
Sentiment note

Reported mixed results with earnings beating estimates but facing Medicare cost pressures and Medicaid attrition

Neutral Investing.com • Timothy Fries
Elevance Health: Solid Q3 Results Support Confident Full-Year Guidance

Elevance Health reported Q3 2025 operating revenue of $50.1 billion, a 12% increase from 2024, with diluted EPS of $5.32. The company maintained full-year guidance despite challenges in Medicaid membership and increased medical costs.

ELV healthcare earnings Medicare Advantage Q3 results financial guidance
Sentiment note

Mixed financial performance with revenue growth but decreased operating gains, offset by confident full-year guidance and strategic investments in technology and workforce

Neutral Benzinga • Vandana Singh
Humana Loses Court Battle Over Medicare Advantage Ratings, Billions In Payments At Risk

Humana lost a legal challenge against federal government cuts to its Medicare Advantage bonus payments, with a Texas judge upholding the downgrade of its star ratings. This ruling could potentially impact billions in revenue for the company.

HUM UNH ELV Medicare Advantage legal challenge star ratings bonus payments healthcare insurance
Sentiment note

Mentioned as having previously won similar legal challenges, with no direct negative impact in this article

Negative GlobeNewswire Inc. • Joshua H. Grabar
Important Notice to Long-Term Shareholders of Elevance Health, Inc. (NYSE: ELV); Humana Inc. (NYSE: HUM); Maison Solutions Inc. (NASDAQ: MSS); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several companies, including Elevance Health, Humana, Maison Solutions, and Vestis Corp, alleging misleading financial statements and undisclosed material risks.

ELV HUM MSS VSTS securities fraud shareholder investigation fiduciary duty class action lawsuit
Sentiment note

Allegations of misleading statements about cost monitoring and premium rate negotiations, particularly regarding Medicaid patient costs

Negative GlobeNewswire Inc. • Grabar Law Office
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf

Law firm investigating potential securities fraud and fiduciary breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that harmed shareholders.

CYTK ELV FLR FLYE securities fraud shareholder investigation class action fiduciary duties
Sentiment note

Allegations of misrepresenting cost trends and patient risk profiles in Medicaid redetermination process

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal